Therma Bright forms deal to boost production of AcuVid COVID-19 tests to meet FDA guidance

Therma Bright Inc CEO Rob Fia tells Proactive it has signed an agreement with a contract manufacturer to produce a weekly minimum of 500,000 AcuVid COVID-19 Rapid Antigen Saliva tests in order to meet the new FDA Emergency Use Authorization guidance on production of diagnostic tests for point-of-care and at-home use.

Fia says the company noted that the contract manufacturer is a European ISO 13845 certified company with deep expertise in diagnostic tests manufacturing and worldwide distribution. In addition to the new manufacturing partner, it has already secured other manufacturers in three markets – Southeast Asia, Mexico and Canada – to produce more than 500,000 AcuVid tests per month.


English English German German